The receptor EP3 to PGE2: A rational target to prevent atherothrombosis without inducing bleeding

Prostaglandins and Other Lipid Mediators

Volumn 121, Issue , 2015, Pages 4-16

  Mawhin, Marie Anne ^a   Tilly, Peggy ^b   Fabre, Jean Etienne ^a  

^a BICHAT HOSPITAL   (France)

^b INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Antiaggregant; Arachidonic acid; BleedingPlatelet; Clopidogrel; DG 041; EP receptors; EP3; Hemostasis; Human; Mice; Myocardial infarction; Paradigm; PGE2; Prevention; Prostanoids; Scratching model

Indexed keywords

3 [1 (2,4 DICHLOROBENZYL) 5 FLUORO 3 METHYL 1H INDOL 7 YL] N [(4,5 DICHLORO 2 THIENYL)SULFONYL]ACRYLAMIDE; ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLIC AMP; PRASUGREL; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; THROMBOXANE A2; THROMBOXANE B2;

ARTICLE; ATHEROSCLEROTIC PLAQUE; BLEEDING TIME; DNA SEQUENCE; FIBRINOLYSIS; HEART INFARCTION; HEMOSTASIS; HOMOLOGOUS RECOMBINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; META ANALYSIS (TOPIC); NONHUMAN; OSSIFICATION; PHASE 3 CLINICAL TRIAL (TOPIC); PLATELET REACTIVITY; PRIMARY PREVENTION; PROSTAGLANDIN SYNTHESIS; PROTEIN TARGETING; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; BIOSYNTHESIS; BLEEDING; CHEMICALLY INDUCED; COMPLICATION; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ATHEROSCLEROSIS; DINOPROSTONE; HEMORRHAGE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; THROMBOSIS;

EID: 84949678559     PISSN: 10988823     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prostaglandins.2015.10.001     Document Type: Review

References (74)

1. K.J. Moore, and I. Tabas Macrophages in the pathogenesis of atherosclerosis Cell 145 2011 341 355
2. M. Naghavi, and et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I Circulation 108 2003 1664 1672
3. J. Ohayon, and et al. Necrotic core thickness and positive arterial remodeling index: emergent biomechanical factors for evaluating the risk of plaque rupture Am. J. Physiol. Heart Circ. Physiol. 295 2008 H717 H727
4. G. Davi, and C. Patrono Platelet activation and atherothrombosis N. Engl. J. Med. 357 2007 2482 2494
5. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N. Engl. J. Med. 352 2005 1685 1695
6. M.R. Law, H.C. Watt, and N.J. Wald The underlying risk of death after myocardial infarction in the absence of treatment Arch. Intern. Med. 162 2002 2405 2410
7. G.W. Stone, and et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
8. D.L. Bhatt Intensifying platelet inhibition-navigating between Scylla and Charybdis N. Engl. J. Med. 357 2007 2078 2081
9. S.D. Wiviott, and et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes N. Engl. J. Med. 357 2007 2001 2015
10. J. Steffel, T.F. Luscher, and F.C. Tanner Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications Circulation 113 2006 722 731
11. M.G. Bousser, and et al. The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study: baseline characteristics of the population Cerebrovasc. Dis. 27 2009 608 613
12. T. Brock, R. McNish, and M. Peters-Golden Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2 J. Biol. Chem. 274 1999 11660 11666
13. S. Gross, P. Tilly, D. Hentsch, J.L. Vonesch, and J.E. Fabre Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors J. Exp. Med. 204 2007 311 320
14. O.A. Belton, A. Duffy, S. Toomey, and D.J. Fitzgerald Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis Circulation 108 2003 3017 3023
15. S. Narumiya Physiology and pathophysiology of prostanoid receptors Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 83 2007 296 319
16. M. Nguyen, and et al. The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth Nature 390 1997 78 81
17. H. Suleyman, A. Albayrak, M. Bilici, E. Cadirci, and Z. Halici Different mechanisms in formation and prevention of indomethacin-induced gastric ulcers Inflammation 33 2010 224 234
18. K. Takeuchi, and E.P. Prostaglandin Receptors and their roles in mucosal protection and ulcer healing in the gastrointestinal tract Adv. Clin. Chem. 51 2010 121 144
19. T. Hoshino, and et al. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation J. Biol. Chem. 278 2003 12752 12758
20. H. Shio, P.W. Ramwell, and S.J. Jessup Prostaglandin E2: effects on aggregation, shape change and cyclic AMP of rat platelets Prostaglandins 1 1972 29 36
21. H. Shio, and P. Ramwell Effect of prostaglandin E2 and aspirin on the secondary aggregation of human platelets Nature 236 1972 45 46
22. D. MacIntyre, and J. Gordon Calcium-dependent stimulation of platelet aggregation by PGE2 Nature 258 1975 337 339
23. S.J. Gray, and S. Heptinstall The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility Eur. J. Pharmacol. 114 1985 129 137
24. S. Gray, and S. Heptinstall Interactions between prostaglandin E2 and inhibitors of platelet aggregation which act through cyclic AMP Eur. J. Pharmacol. 194 1991 63 70
25. R. Vezza, R. Roberti, G.G. Nenci, and P. Gresele Prostaglandin E2 potentiates platelet aggregation by priming protein kinase C Blood 82 1993 2704 2713
26. N. Andersen, L. Eggerman, L. Harker, C. Wilson, and D. Biswanath On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry Prostaglandins 19 1980 713 735
27. B. Ashby Cyclic AMP. turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors Second Messengers Phosphoprot. 12 1988 45 47
28. B. Ashby Interactions among prostaglandin receptors Receptor 4 1994 31 42
29. B.Z.S. Paul, B. Ashby, and S.B. Sheth Distribution of prostaglandin IP and EP receptor subtypes and isoforms in platelets and human umbilical artery smooth muscle cells Br. J. Haematol. 102 1998 1204 1211
30. S. Philipose, and et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation Arterioscler. Thromb. Vasc. Biol. 30 2010 2416 2423
31. G. Petrucci, and et al. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors J. Pharmacol. Exp. Ther. 336 2011 391 402
32. K. Hubertus, and et al. Reciprocal regulation of human platelet function by endogenous prostanoids and through multiple prostanoid receptors Eur. J. Pharmacol. 740 2014 15 27
33. H. Ma, and et al. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3) Circulation 104 2001 1176 1180
34. S. Kuriyama, and et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation Thromb. Haemost. 104 2010 796 803
35. J.E. Fabre, and et al. Activation of the murine EP3 receptor for PGE(2) inhibits cAMP production and promotes platelet aggregation J. Clin. Invest. 107 2001 603 610
36. D. Iyu, and et al. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function Platelets 21 2010 329 342
37. J.P. Smith, E.V. Haddad, J.D. Downey, R.M. Breyer, and O. Boutaud PGE2 decreases reactivity of human platelets by activating EP2 and EP4 Thromb. Res. 126 2010 e23 e29
38. P. Tilly, and et al. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence Cardiovasc. Res. 101 2014 482 491
39. M.A. Feijge, K. Ansink, K. Vanschoonbeek, and J.W. Heemskerk Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3 Biochem. Pharmacol. 67 2004 1559 1567
40. 2+ sequestration and release Biochim. Biophys. Acta 931 1987 49 58
41. 2+ fluxes in human platelet membranes Biochimie 69 1987 297 304
42. J. Enouf, F. Giraud, R. Bredoux, N. Bourdeau, and S. Levy-Toledano Possible role of a cAMP-dependent phosphorylation in the calcium release mediated by inositol 1,4,5-trisphosphate in human platelet membrane vesicles Biochim. Biophys. Acta 928 1987 76 82
43. Y. Cheng, and et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function J. Clin. Invest. 116 2006 1391 1399
44. D. von Elverfeldt, and et al. In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in mice PLoS One 7 2012 e45008
45. J. Singh, and et al. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl) sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding J. Med. Chem. 53 2010 18 36
46. J. Singh, and et al. Antagonists of the EP(3) receptor for prostaglandin E(2) are novel antiplatelet agents that do not prolong bleeding ACS Chem. Biol. 20 2009 115 126
47. S. Heptinstall, and et al. DG-041 inhibits the EP3 prostanoid receptor - a new target for inhibition of platelet function in atherothrombotic disease Platelets 19 2008 605 613
48. N. Mackman Tissue-specific hemostasis in mice Arterioscler. Thromb. Vasc. Biol. 25 2005 2273 2281
49. S.E. Lind The bleeding time does not predict surgical bleeding Blood 77 1991 2547 2552
50. C. Foerch, and et al. Experimental model of warfarin-associated intracerebral hemorrhage Stroke 39 2008 3397 3404
51. S. Narumiya, A. Sugimoto, and F. Ushikubi Prostanoid receptors: structures, properties, and functions Physiol. Rev. 79 1999 1193 1226
52. J. Bruno, and L. Taylor Effects of prostaglandin E2 on human platelet adenyl cyclase and aggregation Nature 251 1974 721 723
53. J.S. Matthews, and R.L. Jones Potentiation of aggregation and inhibition of adenylate cyclase in human platelets by prostaglandin E analogues Br. J. Pharmacol. 108 1993 363 369
54. L.J. Schober, A.L. Khandoga, S.M. Penz, and W. Siess The EP3-agonist sulprostone, but not prostaglandin E2 potentiates platelet aggregation in human blood Thromb. Haemost. 103 2010 1268 1269
55. P. Gresele, D. Blockmans, H. Deckmyn, and J. Vermylen Adenylate cyclase activation determines the effect of thromboxane synthase inhibitors on platelet aggregation in vitro. Comparison of platelets from responders and nonresponders J. Pharmacol. Exp. Ther. 246 1988 301 307
56. L.J. Schober, and et al. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood J. Thromb. Thrombolysis 32 2011 158 166
57. J.A. Grant, and M.C. Scrutton Novel [alpha]2-adrenoreceptors primarily responsible for inducing human platelet aggregation Nature 277 1979 659 661
58. B.K. Kobilka, and et al. Cloning, sequencing, and expression of the gene coding for the human platelet alpha 2-adrenergic receptor Science 238 1987 650 656
59. E.W. Salzman, P.C. Kensler, and L. Levine Cyclic 3′,5′-adenosine monophosphate in human blood platelets IV: regulatory role of cyclic AMP in platelet function Ann. N. Y. Acad. Sci. 201 1972 61 71
60. 2A-Adrenergic receptor stimulation potentiates calcium release in platelets by modulating cAMP levels J. Biol. Chem. 275 2000 1763 1772
61. J.R. O'Brien Some effects of adrenaline and anti-adrenaline compounds on platelets in vitro and in vivo Nature 200 1963 763 764
62. D.C.B. Mills, and G.C.K. Roberts Effects of adrenaline on human blood platelets J. Physiol. 193 1967 443 453
63. R. Seitz, and et al. Possible interaction of platelets and adrenaline in the early phase of myocardial infarction Res. Exp. Med. 187 1987 385 393
64. F. Lanza, and et al. Potentiation by adrenaline of human platelet activation and the inhibition by the alpha-adrenergic antagonist nicergoline of platelet adhesion, secretion and aggregation Agents Actions 18 1986 586 595
65. R. Coleman, W. Smith, and S. Narumya Classification of prostanoid receptors: properties, distribution, and structure of the receptor and their subtypes Pharmacol. Rev. 46 1994 205 228
66. D. Iyu, and et al. PGE1 and PGE2 modify platelet function through different prostanoid receptors Prostaglandins Other Lipid Mediat. 94 2011 9 16
67. J.R. Glenn, A.E. White, D. Iyu, and S. Heptinstall PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors Platelets 23 2012 344 351
68. F. Cipollone, and et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E2-dependent plaque instability Circulation 104 2001 921 927
69. M.L. von Brühl, and et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo J. Exp. Med. 209 2012 819 835
70. K. Kambas, I. Mitroulis, and K. Ritis The emerging role of neutrophils in thrombosis. The journey of TF through NETs Front. Immunol. 3 2012 385
71. A. Mangold, and et al. Coronary neutrophil extracellular trap burden and deoxyribonuclease activity in st-elevation acute coronary syndrome are predictors of ST-segment resolution and infarct size Circ. Res. 116 2015 1182 1192
72. D.R. Holmes, W. Wester, R.W. Thompson, and J.M. Reilly Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms J. Vasc. Surg. 25 1997 810 815
73. J. Smith, C. Ingerman, J. Kocsis, and M. Silver Formation of prostaglandins during the aggregation of human blood platelets J. Clin. Invest. 52 1973 965 969
74. S.C. Fox, and et al. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y(12) antagonist both in-vitro and ex-vivo in human volunteers Platelets 24 2012 392 400